Stay updated with breaking news from Ic1 valneva . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer ....
21st Austria weekly - Valneva 07/09/2023 [pic1]Valneva: Specialty vaccine company and Pfizer announced positive pediatric adolescent immunogenicity safety data for their Lyme disease candidate VLA15 when given as a booster. These results from the VLA15-221 Phase 2 study showed strong anamnestic antibody response all serotypes in 5 to 11 years of age participants 12 17 age well adults 18 65 one month after administration booster dose month 19. “Protection against is important anyone who lives or spends time outdoors areas where endemic. This vital improve our understanding how vaccination may help protect both children this potentially devastating disease ” said Annaliesa Anderson Senior Vice President ....
21st Austria weekly - Valneva Warimpex RHI Magnesita 30/05/2023 [pic1]Valneva: Valneva. an Austrian/French specialty vaccine company today announces the filing of a regulatory application with Health Canada for marketing approval Company’s single-shot chikungunya candidate VLA1553 in persons aged 18 years and above. This is second VLA1553 filed by Company intends to make additional submissions 2023.Valneva: performance: -3.30% Warimpex: The business operations Warimpex Group ....
21st Austria weekly - Valneva Lenzing 14/02/2023 [pic1]Valneva: an Austrian/French specialty vaccine company announced that it completed enrollment and vaccination for a Phase 3 trial in adolescents VLA1553-321 of its single-shot chikungunya candidate VLA1553. First results the are expected mid-2023. The VLA1553-321 adolescent is also to support licensure Europe Brazil which would be first potential approval use endemic populations. Brazil had exponential increase cases 2021 comparison 2020 according data from Brazilian Vigilance Health Secretary ....
21st Austria weekly - Valneva Vienna Stock Exchange 30/12/2022 [pic1]Valneva: an Austrian/French specialty vaccine company reported further heterologous booster data from exploratory small clinical study for its inactivated COVID-19 vaccine VLA2001. The show that a dose of VLA2001 was well tolerated in previously BNT162b2 Pfizer/BioNTech- or mRNA 1273 Moderna-vaccinated participants confirming the favorable safety profile seen across all studies – including homologous settings. However this study additional elicited only marginally increased neutralizing antibody response. Company positive results following primary vaccination with ChAdOx1-S AstraZeneca August ....